Stay updated on Autologous DCs+Tumor Lysate+Nivolumab in Recurrent Glioblastoma Clinical Trial

Sign up to get notified when there's something new on the Autologous DCs+Tumor Lysate+Nivolumab in Recurrent Glioblastoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Autologous DCs+Tumor Lysate+Nivolumab in Recurrent Glioblastoma Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The clinical trial record for guadecitabine plus nivolumab is displayed, with details on the study plan, participant criteria, outcomes, locations, and record history. The previous error page is no longer shown.
    Difference
    50%
    Check dated 2026-11-11T02:18:49.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The site revision label changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-04T01:13:06.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    The page continues to show a 403 Forbidden error instead of the clinical study record.
    Difference
    0.2%
    Check dated 2026-10-28T01:05:22.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    A site-wide NIH announcement about using “Super Intelligence” instead of “Artificial Intelligence” appears above the existing 403 error page. The footer revision label changes from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-21T01:06:23.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.0 to v3.7.1 while the page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-07T01:13:03.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    The page for NCT03576963 now renders a 403 Forbidden response. It replaces the study content with a 403 message and a minimal header, blocking access to the study details.
    Difference
    19%
    Check dated 2026-09-23T01:09:00.000Z thumbnail image

Stay in the know with updates to Autologous DCs+Tumor Lysate+Nivolumab in Recurrent Glioblastoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Autologous DCs+Tumor Lysate+Nivolumab in Recurrent Glioblastoma Clinical Trial page.